Announcements Trials
Browse Landscape

Phase

Phase 2 24Phase 3 7Phase 1 7Phase 1/2 4Phase EARLY_PHASE1 1Phase 2/3 1

Status

Withdrawn 1Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 3NIH 1

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 6Lymphoid 5Gynecologic 4Dermatologic 3Sarcoma 2Head & Neck 2Genitourinary 2Gastrointestinal 2CNS 1

Conditions

Fallopian Tube Neoplasms 2Platinum-Refractory Fallopian Tube Carcinoma 1Ovarian Neoplasms 1Cervical Adenocarcinoma 1

Interventions

Carboplatin 66Paclitaxel 54pembrolizumab 48Cyclophosphamide 33Cisplatin 28Bevacizumab 26Nivolumab 21Gemcitabine 18fludarabine 17liposomal doxorubicin 15Topotecan 15aldesleukin 13Filgrastim 12olaparib 11Interleukin-2 11Docetaxel 11Peripheral Blood Stem Cell Transplantation 10durvalumab 9Taxes 9Specimen Handling 9Oxaliplatin 8fludarabine phosphate 7epacadostat 7Magnetic Resonance Spectroscopy 7Ipilimumab 7Injections 7rucaparib 6niraparib 6lenvatinib 6cemiplimab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1/2 × Disulfides × Gynecologic × Clear all
NCT02726997 2025-12-18

Matched Paired Pharmacodynamics and Feasibility Study of Durvalumab in Combination With Chemotherapy in Frontline Ovarian Cancer (N-Dur)

M.D. Anderson Cancer Center

Phase 1/2 Active not recruiting
18 enrolled
Gynecologic

Fallopian Tube Neoplasms

NCT06543576 2025-08-15

External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer

Jonsson Comprehensive Cancer Center

Phase 1/2 Recruiting
35 enrolled
Gynecologic

Cervical Adenocarcinoma

NCT04019288 2025-06-11

AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

M.D. Anderson Cancer Center

Phase 1/2 Terminated
12 enrolled 13 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06393751 2025-06-03

Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment (Paclitaxel With or Without Bevacizumab) in Patients With Recurrent Ovarian Cancer

National Cancer Institute (NCI)

Phase 1/2 Withdrawn
GynecologicSarcoma

Platinum-Refractory Fallopian Tube Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡